1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Kinase Inhibitor Small Molecule Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Kinase Inhibitor Small Molecule Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Kinase Inhibitor Small Molecule Drugs by Country/Region, 2018, 2022 & 2029
2.2 Kinase Inhibitor Small Molecule Drugs Segment by Type
2.2.1 Receptor Tyrosine Kinase Inhibitors
2.2.2 Non-Receptor Tyrosine Kinase Inhibitors
2.2.3 Serine/Theonine Kinase Inhibitors
2.3 Kinase Inhibitor Small Molecule Drugs Sales by Type
2.3.1 Global Kinase Inhibitor Small Molecule Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Kinase Inhibitor Small Molecule Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Kinase Inhibitor Small Molecule Drugs Sale Price by Type (2018-2023)
2.4 Kinase Inhibitor Small Molecule Drugs Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.5 Kinase Inhibitor Small Molecule Drugs Sales by Application
2.5.1 Global Kinase Inhibitor Small Molecule Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Kinase Inhibitor Small Molecule Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Kinase Inhibitor Small Molecule Drugs Sale Price by Application (2018-2023)
3 Global Kinase Inhibitor Small Molecule Drugs by Company
3.1 Global Kinase Inhibitor Small Molecule Drugs Breakdown Data by Company
3.1.1 Global Kinase Inhibitor Small Molecule Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Kinase Inhibitor Small Molecule Drugs Sales Market Share by Company (2018-2023)
3.2 Global Kinase Inhibitor Small Molecule Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Kinase Inhibitor Small Molecule Drugs Revenue by Company (2018-2023)
3.2.2 Global Kinase Inhibitor Small Molecule Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Kinase Inhibitor Small Molecule Drugs Sale Price by Company
3.4 Key Manufacturers Kinase Inhibitor Small Molecule Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Kinase Inhibitor Small Molecule Drugs Product Location Distribution
3.4.2 Players Kinase Inhibitor Small Molecule Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Kinase Inhibitor Small Molecule Drugs by Geographic Region
4.1 World Historic Kinase Inhibitor Small Molecule Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Kinase Inhibitor Small Molecule Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Kinase Inhibitor Small Molecule Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Kinase Inhibitor Small Molecule Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Kinase Inhibitor Small Molecule Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Kinase Inhibitor Small Molecule Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Kinase Inhibitor Small Molecule Drugs Sales Growth
4.4 APAC Kinase Inhibitor Small Molecule Drugs Sales Growth
4.5 Europe Kinase Inhibitor Small Molecule Drugs Sales Growth
4.6 Middle East & Africa Kinase Inhibitor Small Molecule Drugs Sales Growth
5 Americas
5.1 Americas Kinase Inhibitor Small Molecule Drugs Sales by Country
5.1.1 Americas Kinase Inhibitor Small Molecule Drugs Sales by Country (2018-2023)
5.1.2 Americas Kinase Inhibitor Small Molecule Drugs Revenue by Country (2018-2023)
5.2 Americas Kinase Inhibitor Small Molecule Drugs Sales by Type
5.3 Americas Kinase Inhibitor Small Molecule Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Kinase Inhibitor Small Molecule Drugs Sales by Region
6.1.1 APAC Kinase Inhibitor Small Molecule Drugs Sales by Region (2018-2023)
6.1.2 APAC Kinase Inhibitor Small Molecule Drugs Revenue by Region (2018-2023)
6.2 APAC Kinase Inhibitor Small Molecule Drugs Sales by Type
6.3 APAC Kinase Inhibitor Small Molecule Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Kinase Inhibitor Small Molecule Drugs by Country
7.1.1 Europe Kinase Inhibitor Small Molecule Drugs Sales by Country (2018-2023)
7.1.2 Europe Kinase Inhibitor Small Molecule Drugs Revenue by Country (2018-2023)
7.2 Europe Kinase Inhibitor Small Molecule Drugs Sales by Type
7.3 Europe Kinase Inhibitor Small Molecule Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Kinase Inhibitor Small Molecule Drugs by Country
8.1.1 Middle East & Africa Kinase Inhibitor Small Molecule Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Kinase Inhibitor Small Molecule Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Kinase Inhibitor Small Molecule Drugs Sales by Type
8.3 Middle East & Africa Kinase Inhibitor Small Molecule Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Kinase Inhibitor Small Molecule Drugs
10.3 Manufacturing Process Analysis of Kinase Inhibitor Small Molecule Drugs
10.4 Industry Chain Structure of Kinase Inhibitor Small Molecule Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Kinase Inhibitor Small Molecule Drugs Distributors
11.3 Kinase Inhibitor Small Molecule Drugs Customer
12 World Forecast Review for Kinase Inhibitor Small Molecule Drugs by Geographic Region
12.1 Global Kinase Inhibitor Small Molecule Drugs Market Size Forecast by Region
12.1.1 Global Kinase Inhibitor Small Molecule Drugs Forecast by Region (2024-2029)
12.1.2 Global Kinase Inhibitor Small Molecule Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Kinase Inhibitor Small Molecule Drugs Forecast by Type
12.7 Global Kinase Inhibitor Small Molecule Drugs Forecast by Application
13 Key Players Analysis
13.1 Selleck Chemicals
13.1.1 Selleck Chemicals Company Information
13.1.2 Selleck Chemicals Kinase Inhibitor Small Molecule Drugs Product Portfolios and Specifications
13.1.3 Selleck Chemicals Kinase Inhibitor Small Molecule Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Selleck Chemicals Main Business Overview
13.1.5 Selleck Chemicals Latest Developments
13.2 TargeMol
13.2.1 TargeMol Company Information
13.2.2 TargeMol Kinase Inhibitor Small Molecule Drugs Product Portfolios and Specifications
13.2.3 TargeMol Kinase Inhibitor Small Molecule Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 TargeMol Main Business Overview
13.2.5 TargeMol Latest Developments
13.3 Adooq Bioscience
13.3.1 Adooq Bioscience Company Information
13.3.2 Adooq Bioscience Kinase Inhibitor Small Molecule Drugs Product Portfolios and Specifications
13.3.3 Adooq Bioscience Kinase Inhibitor Small Molecule Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Adooq Bioscience Main Business Overview
13.3.5 Adooq Bioscience Latest Developments
13.4 Santa Cruz Biotechnology
13.4.1 Santa Cruz Biotechnology Company Information
13.4.2 Santa Cruz Biotechnology Kinase Inhibitor Small Molecule Drugs Product Portfolios and Specifications
13.4.3 Santa Cruz Biotechnology Kinase Inhibitor Small Molecule Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Santa Cruz Biotechnology Main Business Overview
13.4.5 Santa Cruz Biotechnology Latest Developments
13.5 Ascentage Pharma
13.5.1 Ascentage Pharma Company Information
13.5.2 Ascentage Pharma Kinase Inhibitor Small Molecule Drugs Product Portfolios and Specifications
13.5.3 Ascentage Pharma Kinase Inhibitor Small Molecule Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Ascentage Pharma Main Business Overview
13.5.5 Ascentage Pharma Latest Developments
13.6 Shanghai Allist Pharmaceuticals
13.6.1 Shanghai Allist Pharmaceuticals Company Information
13.6.2 Shanghai Allist Pharmaceuticals Kinase Inhibitor Small Molecule Drugs Product Portfolios and Specifications
13.6.3 Shanghai Allist Pharmaceuticals Kinase Inhibitor Small Molecule Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Shanghai Allist Pharmaceuticals Main Business Overview
13.6.5 Shanghai Allist Pharmaceuticals Latest Developments
13.7 BioVision
13.7.1 BioVision Company Information
13.7.2 BioVision Kinase Inhibitor Small Molecule Drugs Product Portfolios and Specifications
13.7.3 BioVision Kinase Inhibitor Small Molecule Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 BioVision Main Business Overview
13.7.5 BioVision Latest Developments
13.8 Bio-Techne
13.8.1 Bio-Techne Company Information
13.8.2 Bio-Techne Kinase Inhibitor Small Molecule Drugs Product Portfolios and Specifications
13.8.3 Bio-Techne Kinase Inhibitor Small Molecule Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Bio-Techne Main Business Overview
13.8.5 Bio-Techne Latest Developments
13.9 BOC Sciences
13.9.1 BOC Sciences Company Information
13.9.2 BOC Sciences Kinase Inhibitor Small Molecule Drugs Product Portfolios and Specifications
13.9.3 BOC Sciences Kinase Inhibitor Small Molecule Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 BOC Sciences Main Business Overview
13.9.5 BOC Sciences Latest Developments
13.10 Focus Biomolecules
13.10.1 Focus Biomolecules Company Information
13.10.2 Focus Biomolecules Kinase Inhibitor Small Molecule Drugs Product Portfolios and Specifications
13.10.3 Focus Biomolecules Kinase Inhibitor Small Molecule Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Focus Biomolecules Main Business Overview
13.10.5 Focus Biomolecules Latest Developments
13.11 Aladdin
13.11.1 Aladdin Company Information
13.11.2 Aladdin Kinase Inhibitor Small Molecule Drugs Product Portfolios and Specifications
13.11.3 Aladdin Kinase Inhibitor Small Molecule Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Aladdin Main Business Overview
13.11.5 Aladdin Latest Developments
13.12 Clearsynth
13.12.1 Clearsynth Company Information
13.12.2 Clearsynth Kinase Inhibitor Small Molecule Drugs Product Portfolios and Specifications
13.12.3 Clearsynth Kinase Inhibitor Small Molecule Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Clearsynth Main Business Overview
13.12.5 Clearsynth Latest Developments
13.13 Wuhan Sun-shine Bio-technology
13.13.1 Wuhan Sun-shine Bio-technology Company Information
13.13.2 Wuhan Sun-shine Bio-technology Kinase Inhibitor Small Molecule Drugs Product Portfolios and Specifications
13.13.3 Wuhan Sun-shine Bio-technology Kinase Inhibitor Small Molecule Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Wuhan Sun-shine Bio-technology Main Business Overview
13.13.5 Wuhan Sun-shine Bio-technology Latest Developments
14 Research Findings and Conclusion
※参考情報 キナーゼ阻害剤低分子薬とは、細胞内のシグナル伝達経路に関与する酵素であるキナーゼの働きを抑制するために設計された低分子化合物です。キナーゼは、タンパク質のリン酸化反応を通じて細胞の増殖、分化、生存、アポトーシスなど多岐にわたる生理機能を調節しています。そのため、キナーゼの活性が異常になると、がんや自己免疫疾患、心血管疾患などのさまざまな病態に寄与することがあります。キナーゼ阻害剤は、これらの疾患に対する新しい治療法として注目されています。 キナーゼ阻害剤の特徴には、選択性、効率性、そして副作用のリスクが含まれます。選択性は、ターゲットとなるキナーゼに対して特異的に結合し、他のキナーゼには影響を及ぼさないことを意味します。これにより、正常細胞に対する毒性を減少させることが期待されます。効率性は、治療効果が高いことを示し、ガン細胞の増殖を抑制するなどの効果が求められます。また、副作用は、治療に伴うリスクとして顕在化することがあるため、最小限に抑える必要があります。 キナーゼ阻害剤は、それぞれ異なる機構で機能するため、さまざまな種類があります。たとえば、たんぱく質キナーゼのチロシンキナーゼ、セリン・トレオニンキナーゼ、そしてホスホリパーゼなどが含まれます。チロシンキナーゼは主に細胞増殖や分化に関連し、がん治療に特に重要なターゲットとなります。セリン・トレオニンキナーゼは細胞周期やアポトーシスに関与しており、心血管疾患や代謝症候群などにも影響を与えます。 用途としては、主にがんの治療が挙げられます。現在、市場には多くのキナーゼ阻害剤が承認されており、血液がん(例:慢性骨髄性白血病やホジキンリンパ腫)や固形腫瘍(例:非小細胞肺がんや大腸がん)において、その効果が確認されています。一部のキナーゼ阻害剤は、標的分子治療の一環として、遺伝子異常を持つ患者に特化した治療法としても提供されています。 関連技術としては、ドラッグデリバリーシステムやバイオマーカーの開発が重要です。ドラッグデリバリーシステムは、薬剤を特定の部位に効果的に届けるための技術で、キナーゼ阻害剤の有効成分を腫瘍部位に集中させることができます。これにより、全身への副作用を軽減することが期待されています。また、バイオマーカーは、特定のキナーゼの異常を示す指標として機能し、患者の選択や治療効果の予測に役立ちます。 さらに、キナーゼ阻害剤の研究は日進月歩で進展しており、構造ベースのドラッグデザインや高スループットスクリーニングなどの新しい手法が取り入れられています。これにより、より高い選択性や効率性を持つ新しい化合物の発見が促進されています。また、キナーゼの自己調節メカニズムや細胞内シグナルネットワークの解明が進むことで、抗がん剤の副作用を減少させる新たなターゲットも見つかってきています。 総じて、キナーゼ阻害剤低分子薬は、がんをはじめとするさまざまな疾患の治療において重要な役割を果たしており、その研究は今後も続けられることでしょう。新たな技術や知見が得られることで、より効果的な治療法の開発や副作用の軽減が期待されています。これにより、患者のQOL(生活の質)の向上にも寄与することが求められています。科学の進歩に伴い、キナーゼ阻害剤はより多くの疾患に対する有効な治療手段として位置づけられることになるでしょう。 |
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/